Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors
Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors
复制标题
DOI：
10.1097/iop.0000000000000833
复制
发表时间：
2017-09-01
影响因子：
2
通讯作者：
Freitag, Suzanne K.
中科院分区：
文献类型：
--
作者：
Glass, Lora R. Dagi;Lawrence, Donald P.;Freitag, Suzanne K.
这份报告显示了一个独特的情况下，结膜黑色素瘤窝藏BRAF V600E突变响应全身治疗BRAF和MEK抑制剂。虽然全身性治疗不适合仅局部疾病的患者，但它可能对更高阶段的眼表和眼睑黑色素瘤有治疗作用。
This report demonstrates a unique case of conjunctival melanoma harboring a BRAF V600E mutation responsive to systemic therapy with BRAF and MEK inhibitors. While systemic therapy would not be appropriate in patients with local disease alone, it may act therapeutically in cases of higher stage ocular surface and eyelid melanoma.